What is orforglipron and how effective is it?

Orforglipron is a new daily oral medication that has shown to be more effective for weight loss and blood sugar control than current oral semaglutide products, according to recent trials.

What are the side effects of orforglipron compared to semaglutide?

Orforglipron can cause gastrointestinal side effects like nausea and vomiting, with about 59% of participants reporting such symptoms in a trial, compared to 37-45% for semaglutide. This also led to a higher discontinuation rate for orforglipron.

How does orforglipron differ from injectable GLP-1 drugs like semaglutide?

Orforglipron is an oral small-molecule drug, unlike peptide-based injectables like semaglutide. It does not require refrigeration and is potentially cheaper to manufacture, offering logistical advantages.

Home / Health / New Pill Outperforms Injectable Weight-Loss Drugs

New Pill Outperforms Injectable Weight-Loss Drugs

25 Mar

Summary

New daily pill orforglipron proves more effective than current oral options.
Orforglipron shows superior blood sugar reduction and greater weight loss.
Higher gastrointestinal side effects noted with orforglipron compared to semaglutide.

New Pill Outperforms Injectable Weight-Loss Drugs

A new daily oral medication, orforglipron, is emerging as a significant contender in the weight-loss drug market, showing greater efficacy than current oral semaglutide. Developed by Eli Lilly, this small-molecule drug aims to overcome the limitations of injectable GLP-1 medications.

A recent 52-week phase 3 clinical trial involving 1,698 adults with type 2 diabetes across six countries highlighted orforglipron's effectiveness. Participants taking orforglipron experienced a superior reduction in HbA1c levels and achieved more substantial weight loss compared to those on oral semaglutide.

However, the trial also noted a higher incidence of gastrointestinal side effects, such as nausea and vomiting, among orforglipron users. This led to a greater percentage of participants discontinuing treatment due to adverse effects compared to the semaglutide group.

Orforglipron's small-molecule structure makes it potentially cheaper and simpler to manufacture than peptide-based drugs. Like oral semaglutide, it requires no refrigeration, offering a logistical advantage over injectables, especially for low- and middle-income countries.

Further trials are underway for orforglipron in patients with obesity but without diabetes. The drug's long-term adherence will be crucial, influenced by both its efficacy and tolerability.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.